Abstract
SPP1 was found to be significantly upregulated in many kinds of malignant tumors, including gliomas. Considering that gene polymorphisms have been implicated in the development of gliomas, we performed an association study between SPP1 functional promoter region polymorphisms and glioma risk in a Chinese population. We found significant evidence of an association between SPP1 promoter polymorphisms and glioma risk. For the −155_156insG variant, the −155_156GG allele was found to be significantly associated with an increased risk of glioma (P=0.020, odds ratio (OR)=1.202, 95% confidence interval (CI): 1.028–1.408). Individuals with the genotype containing the GG allele had a 1.372-fold increased risk (P=0.006, OR=1.372, 95% CI: 1.095–1.719). Further stratified analyses suggested that a significant association existed in adult glioma patients, male subjects and in cases without a family history of cancer. Alternatively, the study of single-nucleotide polymorphism −443C/T in a recessive model revealed that the genotype CC + CT significantly decreased the risk of glioma when compared with TT (P=0.023, OR=0.774, 95% CI: 0.621–0.966). After the analysis of haplotypes, the haplotype −155_156GG/−443T was represented at a significantly higher frequency in cases (P=0.029, OR=1.192, 95% CI: 1.018–1.395). Cellular assay indicated that the transcriptional activity of the SPP1 promoter containing the −155_156GG allele significantly increased in glioma cells. Thus, variants of the SPP1 promoter might influence the risk of glioma by regulating promoter activity. Further analyses are necessary to validate our observation in larger samples or in other ethnic groups.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Denhardt, D. T., O’Regan, A. W., Pavlin, D. & Berman, J. S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107, 1055–1061 (2001).
Matusan-Ilijas, K., Behrem, S., Jonjic, N., Zarkovic, K. & Lucin, K. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol. Oncol. Res. 14, 293–298 (2008).
Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S. et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287, 860–864 (2000).
Agnihotri, R., Crawford, H. C., Haro, H., Matrisian, L. M., Havrda, M. C. & Liaw, L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem. 276, 28261–28267 (2001).
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C., Rittling, S. R., Denhardt, D. T. et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731–1735 (2001).
Chiocchetti, A., Indelicato, M., Bensi, T., Mesturini, R., Giordano, M., Sametti, S. et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 103, 1376–1382 (2004).
Jang, T. C., Savarese, T., Low, H. P., Kim, S., Vogel, H., Lapointe, D. et al. Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am. J. Pathol. 168, 1676–1685 (2006).
Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S. & Ushio, Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab. Invest. 72, 55–63 (1995).
Gunnersen, J. M., Spirkoska, V., Smith, P. E., Danks, R. A. & Tan, S. S. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expressin. Glia 32, 146–154 (2000).
Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S. & Yamamoto, S. Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J. 303, 255–262 (1994).
Kim, H. J., Lee, M. H., Kim, H. J., Shin, H. I., Choi, J. Y. & Ryoo, H. M. Okadaic acid stimulates osteopontin expression through de novo induction of AP-1. J. Cell. Biochem. 87, 93–102 (2002).
Renault, M. A., Jalvy, S., Belloc, I., Pasquet, S., Sena, S., Olive, M. et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circ. Res. 93, 674–681 (2003).
Sakata, R., Minami, S., Sowa, Y., Yoshida, M. & Tamaki, T. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem. Biophys. Res. Commun. 315, 959–963 (2004).
Inman, C. K. & Shore, P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J. Biol. Chem. 278, 48684–48689 (2003).
Giacopelli, F., Marciano, R., Pistorio, A., Catarsi, P., Canini, S., Karsenty, G. et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol. Genomics 20, 87–96 (2004).
D’Alfonso, S., Barizzone, N., Giordano, M., Chiocchetti, A., Magnani, C., Castelli, L. et al. Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 52, 539–547 (2005).
Hummelshoj, T., Ryder, L. P., Madsen, H. O., Odum, N. & Svejgaard, A. A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol. Immunol. 43, 980–986 (2006).
Brenner, D., Labreuche, J., Touboul, P. J., Schmidt-Petersen, K., Poirier, O., Perret, C., et al., GENIC Investigators Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients. Stroke 37, 1691–1696 (2006).
Liu, Y., Zhang, H., Zhou, K., Chen, L., Xu, Z., Zhong, Y. et al. Tagging SNPs in nonhomologous end-joining pathway genes and risk of glioma. Carcinogenesis 28, 1906–1913 (2007).
Hendig, D., Arndt, M., Szliska, C., Kleesiek, K. & Götting, C. SPPI promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin. Chem. 53, 829–836 (2007).
Bellahcène, A., Castronovo, V., Ogbureke, K. U., Fisher, L. W. & Fedarko, N. S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat. Rev. Cancer 8, 212–226 (2008).
Brown, L. F., Berse, B., Van De Water, L., Papadopoulos-Sergiou, A., Perruzzi, C. A., Manseau, E. J. et al. Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol. Biol. Cell. 3, 1169–1180 (1992).
Fisher, J. L., Schwartzbaum, J. A., Wrensch, M. & Wiemels, J. L. Epidemiology of brain tumors. Neurol. Clin. 25, 867–890 (2007).
Denhardt, D. T. & Guo, X. Osteopontin: a protein with diverse functions. FASEB J. 7, 1475–1482 (1993).
Dreier, B., Beerli, R. R., Segal, D. J., Flippin, J. D. & Barbas, C. F. Development of zinc finger domains for recognition of the 5 ′-ANN-3′ family of DNA sequences and their use in the construction of artificial transcription factors. J. Biol. Chem. 276, 29466–29478 (2001).
Zhang, R., Min, W. & Sessa, W. C. Functional-analysis of the human endothelial nitric-oxide synthase promoter - SP1 and gata factors are necessary for basal transcription in endothelial-cells. J. Biol. Chem. 270, 15320–15326 (1995).
Ito, Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res. 99, 33–76 (2008).
Armstrong, R. C., Migneault, A., Shegog, M. L., Kim, J. G., Hudson, L. D. & Hessler, R. B. High-grade human brain tumors exhibit increased expression of myelin transcription factor 1 (MYT1), a zinc finger DNA-binding protein. J. Neuropath Exp. Neur. 56, 772–781 (1997).
Acknowledgements
We thank all patients and individuals for their participation. We thank Mr Chunlin Wang and Mr Chun Luo (ChangZheng Hospital) for their expert assistance. This work was supported by a grant from the National 863 project (no. 2007AA02Z483), from the National Natural Science Foundation of China (30772247), from the Shanghai Pujiang Program (08PJ1402200) and from the Shanghai Education Development Foundation (Chenguang Scholar for Qihan Wu).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, J., Wu, Q., Lu, Y. et al. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 55, 456–461 (2010). https://doi.org/10.1038/jhg.2010.48
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2010.48
Keywords
This article is cited by
-
OPN gene polymorphisms, rs17524488 GG/G, rs11730582 T/C and rs9138 C/A and cancer risk in a Chinese population
Scientific Reports (2015)
-
SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV
Hepatology International (2013)